BGMD (BG Medicine) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2015)


What is BG Medicine LT-Debt-to-Total-Asset?

BG Medicine BGMD -99.00% LT-Debt-to-Total-Asset is 0.00 as of Dec. 2015.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BG Medicine's long-term debt to total assests ratio for the quarter that ended in Dec. 2015 was 0.00.

BG Medicine's long-term debt to total assets ratio stayed the same from Dec. 2014 (0.00) to Dec. 2015 (0.00).

BG Medicine  (OTCPK:BGMD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BG Medicine LT-Debt-to-Total-Asset Related Terms

BG Medicine LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BG Medicine's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BG Medicine LT-Debt-to-Total-Asset Chart

BG Medicine Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.43 0.32 0.00 0.00

BG Medicine Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BG Medicine LT-Debt-to-Total-Asset Calculation

BG Medicine's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

LT Debt to Total Assets (A: Dec. 2015 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2015 )/Total Assets (A: Dec. 2015 )
=0/2.133
=0.00

BG Medicine's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2015 is calculated as

LT Debt to Total Assets (Q: Dec. 2015 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2015 )/Total Assets (Q: Dec. 2015 )
=0/2.133
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
BG Medicine (BGMD) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2015. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BG Medicine and its competitors.
Is BG Medicine's LT-Debt-to-Total-Asset too high?
BG Medicine's current LT-Debt-to-Total-Asset is 0.00.
How does BG Medicine's LT-Debt-to-Total-Asset compare to LENSF and WHSI?
BG Medicine's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BG Medicine and its competitors. BG Medicine's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BG Medicine stock overvalued right now?
BG Medicine (BGMD) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BG Medicine (BGMD), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BG Medicine Business Description

Address 303 Wyman Street, Suite 300, Waltham, MA, USA, 02451
BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.